Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease

• DOI: 10.1128/aac.02189-16
• Publication Date: 2016-11-21T22:20:35Z
• Authors: Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L. Daley; Won-Jung Koh
• Keywords: Macrolide Antibiotics; Mycobacterium avium complex

ABSTRACT Macrolide antibiotics are cornerstones in the treatment of Mycobacterium massiliense lung disease. Despite emergence resistance, limited data on macrolide-resistant M . disease available. This study evaluated clinical features and outcomes patients molecular characteristics isolates. We performed a retrospective review medical records genetic analyses isolates from 15 who had between September 2005 February 2015. Nine (60%) nodular bronchiectatic form disease, six (40%) fibrocavitary form. Before detection macrolide three (20%) were treated with monotherapy, four (27%) therapy for presumed avium complex infections, eight (53%) combination antibiotic The median duration after resistance was 18.7 months (interquartile range, 11.2 to 39.8 months). Treatment poor, favorable outcome being achieved only one patient (7%), underwent surgery addition therapy. 1-, 3-, 5-year mortality rates 7, 13, 33%, respectively. Of isolates, 14 (93%) point mutations at position 2058 ( n = 9) or 2059 5) 23S rRNA gene, resulting resistance. Our indicates that poor high development Thus, preventing should be key consideration during treatment.